Hepatitis B virus genotype and mutants: Risk factors for hepatocellular carcinoma

Journal of the National Cancer Institute

Volumn 100, Issue 16, 2008, Pages 1121-1123

  Llovet, Josep M ^a,b,d   Lok, Anna ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b HOSPITAL CLÍNIC   (Spain)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d HCC Research Program

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AFLATOXIN B; ENTECAVIR; HEPATITIS VACCINE; INTERFERON; LAMIVUDINE; TELBIVUDINE; ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN;

APOPTOSIS; CANCER PREVENTION; CANCER RISK; CHEMOEMBOLIZATION; DISEASE COURSE; DNA REPAIR; EDITORIAL; GENE MUTATION; GENOTYPE; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HIGH RISK POPULATION; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VIRUS GENOME; BLOOD; EUROPE; FAR EAST; GENE FREQUENCY; GENETICS; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; LIVER TUMOR; MUTATION; NOTE; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; EUROPE; FAR EAST; GENE FREQUENCY; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MUTATION; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 51049090381     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn261     Document Type: Editorial

References (34)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin. 2005;55(2):74-108.
2. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005-1014.
3. El Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
4. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-1917.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1203.
6. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med. 1997;336:1855-1859.
7. Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J Hepatol. 2002;37:684-695.
8. Ozturk M. Genetic aspects of hepatocellular carcinoma. Semin Liver Disease. 1999;19:235-242.
9. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;20(362):2095-2100.
10. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007;45:579-587.
11. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fi brosis. Ann Intern Med. 2007;147:677-684.
12. Valla DC, Chevallier M, Marcellin P, et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999;29:1870-1875.
13. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
14. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390.
15. Lok A. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127 (5 suppl 1):S303-S309.
16. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;18(347):168-174.
17. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65-73.
18. Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97:265-272.
19. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
20. Baptista M, Kramvis A, Kew MC. High prevalence of 1762(T) 1764(A) mutations in the basic core promoter of hepatitis B virus isolated from black Africans with hepatocellular carcinoma compared with asymptomatic carriers. Hepatology. 1999;29:946-953.
21. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology. 2003;124:327-334.
22. Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of HCC. J Natl Cancer Inst. 2008;100(16):1134-1143.
23. Malmassari SL, Deng Q, Fontaine H, Houitte D, Rimlinger F, Thiers V, Maillere B. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope. Hepatology. 2007;45:1199-1209.
24. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007;26:2166-2176.
25. Chou YC, Yu MW, Wu CF, et al. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut. 2008;57:91-97.
26. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 2002;122:1756-1762.
27. Tanaka Y, Mukaide M, Orito E, et al. Specifi c mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. J Hepatol. 2006;45:646-653.
28. Chan HL, Tse CH, Mo F, et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008;26:177-182.
29. Hoofnagle JH, Doo E, Liang TJ, et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45:1056-1075.
30. Hoofnagle JH. Hepatitis B - preventable and now treatable. N Engl J Med. 2006;354:1074-1076.
31. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521-1531.
32. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354:1001-1010.
33. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007;20(357):2576-2588.
34. Llovet JM, Di Bisceglie A, Bruix J, et al. Design and end-points of clinical trials in HCC. J Natl Cancer Inst. 2008;100:698-711.